explore -WSS

explore

author：Wikipedia 2025-09-29 22:49:57 - browse：194

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Patients' immediate access to test results puts radiologists in a bind

leisure time

WSS

US jobless claims fall again as labor market continues to flash strength

Pfizer plans to depart BIO

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Sanders wants to replace patents with prizes for drug inventions

SCOTUS to consider access to abortion pill mifepristone

A new ‘biological computer' targets cancer while sparing healthy cells

hotspot

explore

focus

Novavax promises a turnaround & Lilly roils the obesity market

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Hollywood unions extend contract negotiations for actors

Dementia risk linked to living in disadvantaged areas: Study

Trump demands the U.S. pay no more for drugs than other countries … again

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Medicare proposal to cover medical devices draws a mixed reaction

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Hollywood unions extend contract negotiations for actors

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

entertainment

After sickle

Sanders wants to replace patents with prizes for drug inventions

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Scientists grapple with ethics of stem cell research

STAT letters to the editor on burnt

US jobless claims fall again as labor market continues to flash strength

hotspot

leisure time

hotspot

hotspot